A diabetes visit can feel centered on one result: your A1C. The 2026 American Diabetes Association Standards of Care make clear that good care involves much more than that number.
The updates bring earlier consideration of continuous glucose monitoring, more attention to overlapping heart, kidney, liver, and weight conditions, and a stronger emphasis on changing a plan when it is not working. They do not mean every adult with type 2 diabetes needs the same device, medicine, or blood-pressure target.
Why the 2026 Standards matter in primary care
The ADA Standards of Care are updated regularly as evidence changes. They help clinicians connect glucose management with the complications and practical challenges that affect everyday life. For a broader view of how treatment has been shifting, see our overview of current trends in diabetes treatment.
For patients, the useful takeaway is to expect a review of the whole plan. Are glucose levels safe? Are you having lows? Is a medication addressing the condition it was chosen for? Is cost preventing you from following the prescription?
An updated guideline should make that conversation more precise. It should not turn a stable, workable plan into a source of unnecessary alarm.
Earlier CGM: who may be offered a monitor?
The 2026 pharmacologic-treatment recommendations recommend continuous glucose monitoring at diabetes onset and later for adults using insulin, using noninsulin medicines that can cause hypoglycemia, or receiving other diabetes treatment when CGM helps management.
That broadens the discussion beyond “CGM is only for people on insulin.” A monitor may reveal patterns that a single finger-stick or an A1C cannot show, such as overnight lows or a repeated rise after a particular meal.
The device still needs a purpose. Ask what question the team is trying to answer, how the information will be reviewed, and what training or supplies are needed. Coverage does not automatically follow a guideline recommendation.
Our existing article on CGM for type 2 diabetes without insulin explores that specific question. The 2026 update adds context for discussing it at a routine visit.
Diabetes care is also heart, kidney, and liver care
The ADA’s summary of 2026 revisions includes updated recommendations for selected people with overlapping conditions.
For example, adults with type 2 diabetes, obesity, and symptomatic heart failure with preserved ejection fraction may be considered for particular GLP-1 receptor agonist or dual GIP/GLP-1 therapies with demonstrated benefits. The Standards also address incretin-based therapy in certain kidney and metabolic liver-disease situations.
This does not mean every medicine in a class has the same evidence or that one drug treats all three organs. SGLT2 inhibitors and other established therapies also remain important for appropriate heart and kidney indications.
Ask your clinician to explain the reason for each medicine: glucose control, cardiovascular benefit, kidney protection, weight management, or more than one goal. An A1C already near target does not necessarily settle every medication decision.
Terms such as MASLD and MASH describe forms of metabolic liver disease. If they come up, ask what evaluation is actually needed in your case rather than assuming every person with diabetes has advanced liver disease.
Blood-pressure targets: lower for some people, not everyone
The 2026 ADA cardiovascular standards maintain an on-treatment goal below 130/80 mm Hg when safely achievable and encourage a systolic goal below 120 for people at high cardiovascular or kidney risk.
That more intensive systolic target is not a universal mandate. Dizziness, falls, medication burden, frailty, and other conditions can affect the balance of benefit and harm.
If a clinician proposes a lower target, ask how it will be measured, what symptoms to report, and when the treatment will be reassessed. Do not increase your own medication to chase a number from an article. Our high blood pressure care page explains how blood pressure is confirmed and followed alongside diabetes.
“Therapeutic inertia”: why a stalled plan deserves attention
Therapeutic inertia means not adjusting treatment when a change is needed. The 2026 Standards explicitly identify avoiding it as part of care.
That does not mean adding medication at every appointment. The necessary change may be addressing side effects, simplifying a schedule, improving access, reviewing injection technique, arranging nutrition support, or reconsidering a target that is too burdensome. Our article on primary-care strategies for controlling type 2 diabetes covers several of these practical adjustments.
For example, a repeated high A1C after an insurance denial calls for an affordable plan, not another reminder to take a medicine you cannot obtain. Recurrent low glucose needs attention even when the average A1C looks “good.”
Leave the visit knowing the next step and when the team will evaluate whether it helped. A plan without a follow-up point is difficult to improve.
Coordinating diabetes, nutrition, and weight care in Allen
A useful diabetes visit can bring together glucose patterns, blood pressure, kidney results, medication response, nutrition, activity, and weight goals. The relevant priorities differ from person to person.
Bring meter or CGM information, a medication list, home blood-pressure readings if requested, and examples of barriers you are encountering. If you are frequently skipping meals, struggling with medication cost, or unsure how to interpret a low-glucose alert, say so.
A registered dietitian can help translate broad advice into meals that fit your preferences, schedule, cultural foods, and medical needs. Nutrition support should complement medication management rather than become a test of willpower.
RescueMD offers diabetes care, registered dietitian services, structured follow-up through the A1C Accelerator, and medical weight-management care. If you are searching for diabetes treatment near you, call 972-390-7667 to request a visit at 945 Stockton Drive, Suite 6100, Allen, TX 75013. Nearby communities are served from this Allen clinic.
Frequently asked questions
If I am not on insulin, can I still be a candidate for CGM?
Yes. It may be appropriate when a medicine creates low-glucose risk or when the information would help management. The clinical purpose, device choice, training, and insurance coverage need review.
Does a lower blood-pressure target apply to every adult with diabetes?
No. More intensive targets apply to selected patients and must be safe and tolerable. Your clinician should individualize the goal.
Will my medications change because of the new Standards?
Not automatically. Changes depend on your results, diagnoses, symptoms, risks, preferences, and access—not the publication date alone.
Where does a registered dietitian fit?
A dietitian can help with practical food choices, meal timing, weight goals, and nutrition challenges. That support works alongside the clinician’s treatment plan.
Continue prescribed care unless your clinician advises a change. This article explains guidance and does not provide an individual medication or monitoring plan.